Primary Outcomes
Measure: Number of patients with epidermal growth factor receptor (EGFR) positive mutation among advanced or metastatic non-small-cell lung cancer (NSCLC) patients in Galicia Time: 10 months (recruitment period)
Secondary Outcomes
Measure: Epidermal growth factor receptor (EGFR) mutational status in tumor tissue (primary tumor or metastatic samples) and plasma samples at screening Time: 1 day (Screening Visit)
Measure: Type of epidermal growth factor receptor (EGFR) mutations: deletion in exon 19, point mutation at codon 858 (L858R) or other (only for EGFR M+ patients) Time: 1 day (Screening Visit)
Measure: Prescribed first line treatment (only for epidermal growth factor receptor (EGFR) M+ patients) Time: 1 day (First study visit)
Measure: Tumor response (only for epidermal growth factor receptor (EGFR) M+ patients) Time: From inclusion until disease progression, death or until 9 months from the inclusion of the last patient in the study have elapsed, whichever is earlier.
Measure: Disease control (only for epidermal growth factor receptor (EGFR) M+ patients) Time: From inclusion until the end of the study (9 months subsequent to the last patient's inclusion or until lost of follow-up)
Measure: Prescribed second-line treatment after progression (only for epidermal growth factor receptor (EGFR) M+ patients) Time: 1 day (Progression Visit)
Measure: Progression-free survival and overall survival (only for epidermal growth factor receptor (EGFR) M+ patients) Time: 1 day (at the end of the study 9 months subsequent to the last patient's inclusion or until lost of follow-up
Measure: Epidermal growth factor receptor (EGFR) mutational status at disease progression in tumor tissue (primary tumor or metastatic samples) and plasma samples (only for EGFR M+ patients) Time: 1 day (Progresion Visit)